SCHEMBL27446266

SCHEMBL27446266

Cc1ccc(Nc2nccc(-c3cccc(N)c3)n2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 5/20 0.77
CDK5 Q00535 2/20 0.76
MEN1 O00255 1/20 0.76
NPC1 O15118 1/20 0.76
RAB9A P51151 1/20 0.76
KMT2A Q03164 1/20 0.76
CDK5R1 Q15078 1/20 0.76
CAMK2D Q13557 1/20 0.67
JAK2 O60674 1/20 0.65
ABL1 P00519 4/20 0.62
BCR P11274 4/20 0.62
SRC P12931 2/20 0.62
EGFR P00533 1/20 0.62
PRKACA P17612 1/20 0.62
PRKACG P22612 1/20 0.62
PRKACB P22694 1/20 0.62
KARS1 Q15046 1/20 0.55
BRD4 O60885 1/20 0.54
CDK9 P50750 1/20 0.54
CDK4 P11802 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12801287 0.91 PLK1 (0.82) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL27444270 0.88 PLK1 (0.78) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL4907230 0.87 PLK1 (1.00) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL4737495 0.87 PLK1 (0.77) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL823915 0.86 CAMK2D (0.82) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL12801281 0.86 PLK1 (0.72) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL25337631 0.84 PLK1 (0.72) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL30554478 0.84 PLK1 (0.72) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL27444229 0.83 PLK1 (0.57) PLK1CDK5MEN1NPC1RAB9A
SCHEMBL31119008 0.83 PLK1 (0.74) PLK1CDK5MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 PLK1 4810/4885CDK5 3223/4885MEN1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.